At Epizyme, we are a commercial-stage biopharmaceutical company that is committed to rewriting treatment for people with cancer through the discovery, development, and commercialization of novel epigenetic medicines.
We aspire to change the standard of care for patients and physicians by developing targeted medicines with fundamentally new mechanisms of action directed at specific causes of hematological malignancies and solid tumors.
Our vision, which we refer to as The Next EPIsode™: Rewriting Oncology Treatment with Epigenetics, is focused on four critical imperatives:
We are focused on maximizing our effectiveness as a commercial organization to achieve adoption of TAZVERIK® (tazemetostat) among as many eligible follicular lymphoma (FL) and epithelioid sarcoma (ES) patients as possible, including in earlier treatment lines and in combination regimens with the data to support this expanded use.
We are building on TAZVERIK’s pipeline-in-a-drug potential, demonstrating tazemetostat’s potential benefit in additional hematological malignancies and solid tumors.
Our plans include expanding our pipeline and evolving oncology portfolio, to bring novel oncology therapeutics into clinical development to maintain our position as a leader in epigenetics.
We will expand our patient reach and increase shareholder value through commercial, clinical, and research collaborations.